6-K ·Filed Sep 9, 2026

NVO

NOVO NORDISK A S
NEUTRAL
Impact 2/10
Horizondays Processed23d 2h ago SEC0001171843-26-005925
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative — no change in buyback pace or strategy. Monitor future filings for any modification to the program or material corporate events. For a $200B market cap company, weekly buyback disclosures of this magnitude are not price-relevant.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+5d
NVO ▼ -6.40% at T+5d
NEUTRAL call ✗ call lost -6.40% · α vs SPY -5.74% · entry $44.56 → $41.71
Next anchor: T+20d in 5d
Latest observation: T+16 -12.80% FF3 residual α
Entry anchored
Sep 9, 05:59 AM ET
via 1-min bar
T+1d
-1.23%
call -1.23% · α -0.63%
$44.01
settled 22d ago
T+5d
-6.40%
call -6.40% · α -5.74%
$41.71
settled 16d ago
T+20d
—
call — · α —
—
in 5d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 15 billion buyback program. The company repurchased ~1.06M B shares for ~DKK 314.1M during the week of August 31–September 4, 2026, at an average price of ~DKK 297.5 per share. This is a standard periodic disclosure with no new material information — the buyback was announced months ago and is proceeding as planned.

Key Facts

  • Novo Nordisk repurchased 1,055,000 B shares during August 31–September 4, 2026, for a total transaction value of approximately DKK 314.1 million.
  • Accumulated repurchases under the program initiated May 6, 2026: 17,275,000 B shares for approximately DKK 5.22 billion.
  • Total repurchases since the broader 12-month program began February 4, 2026: 32,034,179 B shares for approximately DKK 9.02 billion, at an average price of DKK 281.63 per share.
  • Novo Nordisk now holds 46,074,876 B shares as treasury shares, representing 1.0% of total share capital of 4,465,000,000 A and B shares.
  • The overall program authorizes up to DKK 15 billion in repurchases over 12 months from February 4, 2026.

Financial Impact

Routine buyback execution — approximately DKK 314.1M in repurchases for the week. No new authorization or change in program size.

share counttreasury shares

Risk Factors

  • None — this is a routine disclosure of ongoing share repurchases with no new authorization or change in terms.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
31% bullish (36 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005925
Document: 0001171843-26-005925-index-headers.html0001171843-26-005925
Document: 0001171843-26-005925-index.html0001171843-26-005925
Document: 0001171843-26-005925.txt0001171843-26-005925
26 reports for NVO
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+20▲ +14.18%Jun 10, 2026
Filters
Rows
Reports for NVO — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 3/10
$42.53 $39.40▼ −7.36%▼ −9.49%$37.32 (−12.25%)
Sep 9, 2026
23d ago
6-K
NEUTRAL ★ 2/10
$44.56 $41.71▼ −6.40%▼ −5.74%$37.32 (−16.25%)
Sep 8, 2026
24d ago
Court Ruling
NEUTRAL ★ 1/10
$45.16 $42.53▼ −5.82%▼ −4.70%$37.32 (−17.36%)
Sep 3, 2026
29d ago
Court Ruling
NEUTRAL ★ 1/10
$47.51 $43.07▼ −9.35%▼ −8.20%$37.32 (−21.45%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$46.92 $45.33▼ −3.39%▼ −3.86%$37.32 (−20.46%)
Aug 18, 2026
6w ago
6-K
NEUTRAL ★ 2/10
$45.71 $48.66▲ +6.45%▲ +6.65%$37.32 (−18.35%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$47.73 $44.88▼ −5.97%▼ −5.92%$37.32 (−21.81%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$47.73 $44.88▼ −5.97%▼ −5.92%$37.32 (−21.81%)
Aug 4, 2026
8w ago
6-K
MIXED ★ 6/10
$44.28 $47.17▲ +6.53%▲ +6.63%$37.32 (−15.72%)
Aug 4, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$44.28 $47.17▲ +6.53%▲ +6.63%$37.32 (−15.72%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (64h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access